Catalyst Pharmaceuticalsincis A Biopharmaceutical Company Based In Coral Gablesfloridafocused On Developing And Commercializing Treatments For Rare Diseasesfounded In 2002Catalyst Is Publicly Traded On Nasdaq Under The Ticker Cprx And Is Part Of The Russell 2000 And S&P 600 Indicesthe Company Is Dedicated To Enhancing The Lives Of Patients With Rare Diseases Through Innovative Therapies And Comprehensive Support Services Catalyst S Product Portfolio Includes Firdapseapproved For Lambert Eaton Myasthenic Syndromefycompa For Partial Onset Seizuresand Agamree For Duchenne Muscular Dystrophythe Company Distributes Its Products Through A Field Force And Specialty Pharmaciesprimarily In The U S With A Subsidiary In Irelandcatalyst Emphasizes Accessibility And Support For Patients And Their Familiesensuring They Receive The Care They Need
